Department of Dermatology and Allergy, Dermatological Allergology, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Division of Allergy, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
Front Immunol. 2021 May 25;12:675451. doi: 10.3389/fimmu.2021.675451. eCollection 2021.
Cryoproteins, such as cryoglobulins, cryofibrinogens and cold agglutinins, precipitate at low temperatures or agglutinate erythrocytes and dissolve again when warmed. Their pathogenetic and diagnostic importance in cold urticaria (ColdU) is unclear. In this study, we aimed to characterize the prevalence of cryoproteins in patients with ColdU.
We conducted 3 analyses: i) a systematic review and meta-analysis of published data using an adapted version of the Joanna Briggs Institute's critical appraisal tool for case series, ii) a retrospective analysis of 293 ColdU patients treated at our Urticaria Center of Reference and Excellence (UCARE) from 2014 to 2019, and iii) a prospective observational study, from July 2019 to July 2020, with 49 ColdU patients as defined by the EAACI/GA2LEN/EDF/UNEV consensus recommendations.
Our systematic review identified 14 relevant studies with a total of 1151 ColdU patients. The meta-analyses showed that 3.0% (19/628), 1.1% (4/357) and 0.7% (2/283) of patients had elevated levels of cryoglobulins, cryofibrinogens and cold agglutinins, respectively. Our retrospective analyses showed that cryoproteins were assessed in 4.1% (12/293) of ColdU patients. None of 9 ColdU patients had cryoglobulins, and one of 5 had cold agglutinins. In our prospective study, none of our patients had detectable cryoglobulins (0/48) or cryofibrinogens (0/48), but 4.3% (2/46) of patients had cold agglutinins (without any known underlying autoimmune or hematological disorder).
Our investigation suggests that only very few ColdU patients exhibit cryoproteins and that the pathogenesis of ColdU is driven by other mechanisms, which remain to be identified and characterized in detail.
冷冻蛋白(如冷球蛋白、冷纤维蛋白原和冷自身抗体)在低温下沉淀或凝集红细胞,当温度升高时又溶解。它们在冷性荨麻疹(ColdU)中的致病和诊断意义尚不清楚。在这项研究中,我们旨在描述 ColdU 患者中冷冻蛋白的患病率。
我们进行了 3 项分析:i)使用经过改编的 Joanna Briggs 研究所病例系列批判性评价工具对已发表数据进行系统回顾和荟萃分析;ii)对 2014 年至 2019 年在我们的荨麻疹参考和卓越中心(UCARE)治疗的 293 例 ColdU 患者进行回顾性分析;iii)一项前瞻性观察性研究,从 2019 年 7 月至 2020 年 7 月,纳入了 49 例符合 EAACI/GA2LEN/EDF/UNEV 共识建议的 ColdU 患者。
我们的系统回顾确定了 14 项相关研究,共纳入了 1151 例 ColdU 患者。荟萃分析显示,3.0%(19/628)、1.1%(4/357)和 0.7%(2/283)的患者冷球蛋白、冷纤维蛋白原和冷自身抗体水平升高。我们的回顾性分析显示,4.1%(12/293)的 ColdU 患者评估了冷冻蛋白。9 例 ColdU 患者均未检出冷球蛋白,5 例中有 1 例检出冷自身抗体。在我们的前瞻性研究中,我们的患者均未检出冷球蛋白(0/48)或冷纤维蛋白原(0/48),但有 4.3%(2/46)的患者检出冷自身抗体(无已知的自身免疫或血液学疾病)。
我们的研究表明,只有极少数 ColdU 患者存在冷冻蛋白,ColdU 的发病机制可能由其他机制驱动,这些机制仍有待详细识别和描述。